Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR 2020 round-up: Our biggest cancer stories of the year December 20, 2020 Deaf Football Team Makes History, Heads To School’s First Finals Game... November 24, 2021 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 Happy Holidays from the OncoLink Team December 7, 2023 Load more HOT NEWS News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable...
